As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > COMMENTARY
COMMENTARY
-
How Not to License a Drug into Japan
October 12, 2009
-
TOPICS/Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
-
NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
-
COMMENTARY/Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
-
COMMENTARY/Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
-
COMMENTARY/Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
-
COMMENTARY/Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
-
COMMENTARY/Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
-
COMMENTARY/Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
-
COMMENTARY/Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
-
COMMENTARY/Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
-
COMMENTARY/Global Pharmas Enhance Their Presence in Japan
July 13, 2009
-
COMMENTARY/Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
-
COMMENTARY/Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
-
SURVEY/RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
-
COMMENTARY/JSHP to Promote Use of Generics
June 8, 2009
-
COMMENTARY/Combination Drugs Becoming a "Boom"
June 1, 2009
-
COMMENTARY/Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…